Drug Profile
Tigilanol tiglate - QBiotics
Alternative Names: EBC 46Latest Information Update: 18 Aug 2023
Price :
$50
*
At a glance
- Originator QBiotics
- Developer Cardiff University; Merck Sharp & Dohme; QBiotics; Swansea University Medical School
- Class Antibacterials; Antineoplastics; Diterpenes; Esters; Small molecules
- Mechanism of Action Immunostimulants; Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer; Malignant melanoma; Soft tissue sarcoma
- Phase I/II Solid tumours
- No development reported Bacterial infections
Most Recent Events
- 16 Aug 2023 Adverse events data from a phase I trial for Head and neck cancer released by QBiotics
- 28 Jul 2023 No recent reports of development identified for preclinical development in Bacterial-infections in Australia
- 30 Jun 2023 Efficacy and adverse events data from a phase Ib/IIa trial in Malignant melanoma released by QBiotics